Skip to main content
. 2020 Nov 2;2(2):fcaa183. doi: 10.1093/braincomms/fcaa183

Figure 6.

Figure 6

Predicted versus observed PSL plasma concentrations. Predicted values were obtained from a population pharmacokinetic model built on data from the proof-of-concept trial and the PET studies, and indicated that PSL concentrations following the 400 mg bid dosing regimen would allow desired target occupancy for both SV2A and GABAA receptors to be achieved.